AACR 2024 Poster 87

Integrated Pipeline for Immuno-oncology Drug Testing: From Patient-derived Organoid Assays with Reconstituted TME to Fresh Ex Vivo Patient Tissue Cultures

Ezgi Kaya Aksoy, Sergei Chavez Abiega, Talita Stessuk, Saskia de Man, Marrit Putker, Sander Basten, Jolie Flach, Niels Meesters, Emma Spanjaard, Leo Price, Gera Goverse, and Nataliia Beztsinna

Successful preclinical evaluation of immuno-oncology drugs requires complex models to accurately represent all components of the human tumor microenvironment (TME). There are two promising approaches available for preclinical studies to more accurately represent the TME, each with advantages and limitations. In our immuno-oncology in vitro assays, PDOs can be combined with immune cells and fibroblasts to re-constitute the TME. Alternatively, assays with fresh tumor material containing native TME in the 3D Ex Vivo Patient Tissue (EVPT) platform can be utilized.

The study presented in this poster compares the two approaches.

Download this Poster to Discover:

• Study method including patient tumor tissue procurement and processing and method to generate, biobank, and characterize PDOs.
• Ex vivo sample’s responses to immune-stimulatory compounds in EVPT platform and co-culture responses of M1 organoids.
• A spectrum of assays ranging from complex ex vivo fresh tissue cultures (EVPT) for ‘close to the clinic’ scenarios to more scalable PDO models co-cultured with allogeneic and/or autologous PBMCs for high-throughput mechanistic drug screenings.

Download the Poster Now!